Fig. 2From: Optimal sequencing of the first- and second-line target therapies in metastatic renal cell carcinoma: based on nationally representative data analysis from the Korean National Health Insurance SystemTotal number of targeted therapy agent prescription from 2011 until 2020Back to article page